Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: An increasingly achievable outcome with subsidence of disease symptoms

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 867-873

  Ajeganova, S ^a,b   Van Steenbergen, H W ^a   Van Nies, J A B ^a   Burgers, L E ^a   Huizinga, T W J ^a   Van Der Helm Van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; AGED; ARTHRITIS, RHEUMATOID; BLOOD; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84963754725     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-207080     Document Type: Article

References (22)

1. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
2. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
3. Harrison BJ, Symmons DP, Brennan P, et al. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996;35:1096-100.
4. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthitis Rheum 2009;60:2262-71.
5. van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford) 2012;51:1120-8.
6. Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010;39:12-18.
7. de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011;50:93-100.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Burgers LE, van Nies JA, Ho LY, et al. Long-term outcome of rheumatoid arthritis defined according to the 2010-classification criteria. Ann Rheum Dis 2014;73:428-32.
10. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11:R7.
11. Sokka T, Makinen H, Hannonen P, et al. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1020-3.
12. Krishnan E, Sokka T, Hakkinen A, et al. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953-60.
13. Sokka T. Assessment of pain in rheumatic diseases. Clin Exp Rheumatol 2005;23:S77-84.
14. Slatkowsky-Christensen B, Mowinckel P, Loge JH, et al. Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis Rheum 2007;57:1404-9.
15. Bellamy N, Wilson C, Hendrikz J. Population-based normative values for the Western Ontario and McMaster (WOMAC) Osteoarthritis Index: part I. Semin Arthritis Rheum 2011;41:139-48.
16. Bellamy N, Wilson C, Hendrikz J. Population-based normative values for the Australian/Canadian (AUSCAN) Hand Osteoarthritis Index: part 2. Semin Arthritis Rheum 2011;41:149-56.
17. Pincus T, Sokka T, Chung CP, et al. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis 2006;65:878-83.
18. Putrik P, Ramiro S, Keszei AP, et al. Patients from wealthier countries perform better on clinical disease activity measures, but show worse person reported outcomes [abstract]. Ann Rheum Dis 2014;73(Suppl 2):75.
19. van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861-70.
20. Wevers-de Boer K, Visser K, Heimans L, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012;71:1472-7.
21. O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 2013;65:1985-94.
22. Ma MH, Scott IC, Dahanayake C, et al. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen. J Rheumatol 2014;41:1298-303.